Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Rhea-AI Summary

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the H.C. Wainwright BioConnect Investor Conference in New York City on May 2, 2023. The event will feature a Fireside Chat scheduled for 10 AM ET. A webcast link for the presentation is available online. Following the live event, a replay will be archived for 90 days on Compass's Events page. Compass Therapeutics is focused on developing proprietary antibody-based therapeutics targeting oncology, aiming to engage multiple critical biological pathways for effective anti-tumor responses. Founded in 2014 and based in Boston, the company is dedicated to advancing its clinical pipeline with novel product candidates.

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the H.C. Wainwright BioConnect Investor Conference in New York City on Tuesday, May 2, 2023.

Fireside Chat details:
Date: Tuesday, May 2
Time: 10 AM ET
Webcast: https://journey.ct.events/view/059d01ae-0fdd-4419-8329-ac44f76cc2fc

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099

FAQ

What is the date and time of Compass Therapeutics' Fireside Chat at the H.C. Wainwright BioConnect Investor Conference?

Compass Therapeutics' Fireside Chat is scheduled for May 2, 2023, at 10 AM ET.

Where can I watch the Compass Therapeutics Fireside Chat?

The Fireside Chat can be viewed via a webcast link provided in their press release.

How long will the Compass Therapeutics presentation be available for replay?

The presentation will be archived for 90 days following the event.

What is the focus of Compass Therapeutics as a biopharmaceutical company?

Compass Therapeutics focuses on developing antibody-based therapeutics primarily targeting oncology.

When was Compass Therapeutics founded?

Compass Therapeutics was founded in 2014.